Beta Bionics Q3 2025 Financial Results and Guidance Update

Beta Bionics, Inc. reported its financial results for the third quarter ended September 30, 2025, and raised its full-year guidance. The company achieved net sales of $27.3 million, a 63% increase compared to the same period in 2024. The Durable Medical Equipment (DME) channel contributed $21.0 million, up 45%, while the Pharmacy Benefit Plan (PBP) channel saw a 178% increase to $6.2 million. Gross margin improved to 55.5%, up 212 basis points. The company reported a net loss of $14.2 million, or 52% of sales, compared to a net loss of $9.7 million, or 58% of sales, in Q3 2024. Beta Bionics also updated its full-year 2025 guidance, projecting total revenue of greater than $96.5 million, up from the previous range of $88 million to $93 million. The company highlighted strategic achievements, including formulary agreements with major PBMs and the completion of a glucagon pharmacokinetic trial.